{"id":"NCT02542696","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of \"OFF\" Episodes in Patients With Parkinson's Disease","officialTitle":"An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08-31","primaryCompletion":"2022-11-08","completion":"2022-11-08","firstPosted":"2015-09-07","resultsPosted":"2023-11-22","lastUpdate":"2023-11-22"},"enrollment":496,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson Disease"],"interventions":[{"type":"DRUG","name":"APL-130277","otherNames":["Apomorphine Hydrochloride, Sublingual Thin Film"]}],"arms":[{"label":"APL-130277","type":"EXPERIMENTAL"}],"summary":"An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of \"OFF\" Episodes in Patients With Parkinson's Disease","primaryOutcome":{"measure":"Evaluation of Safety and Tolerability Data Collected, Based on Number of Participants With Adverse Events in the LTS Phase","timeFrame":"up to approximately 3 years","effectByArm":[{"arm":"APL-130277","deltaMin":365,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":70,"countries":["United States","Austria","Canada","France","Germany","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":496},"commonTop":["Nausea","Somnolence","Yawning","Dizziness","Fall"]}}